Get the Stockscreener App
4.49
1.13%
0.05
After Hours:
4.42
-0.07
-1.56%
Unicycive Therapeutics Inc stock is traded at $4.49, with a volume of 252.54K.
It is up +1.13% in the last 24 hours and up +16.02% over the past month.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
See More
Previous Close:
$4.44
Open:
$4.56
24h Volume:
252.54K
Relative Volume:
0.56
Market Cap:
$79.30M
Revenue:
-
Net Income/Loss:
$-30.54M
P/E Ratio:
-2.8968
EPS:
-1.55
Net Cash Flow:
$-18.30M
1W Performance:
-2.39%
1M Performance:
+16.02%
6M Performance:
+719.94%
1Y Performance:
+1,114%
1-Day Range:
$4.325
$4.5799
1-Week Range:
$4.325
$4.87
52-Week Range:
$0.3705
$8.2457
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
Name
Unicycive Therapeutics Inc
Sector
Industry
Phone
650-384-0642
Address
4300 EL CAMINO REAL, SUITE 210, LOS ALTOS
Compare UNCY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
4.49 | 78.42M | 0 | -30.54M | -18.30M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-25 | Initiated | Guggenheim | Buy |
| Apr-04-24 | Initiated | Piper Sandler | Overweight |
Unicycive Therapeutics Inc Stock (UNCY) Latest News
Pomerantz Law Firm Announces the Filing of a Class Action Against Unicycive Therapeutics, Inc. and Certain OfficersUNCY - PR Newswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics - The AI Journal
UNCY INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
UNICYCIVE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges - GlobeNewswire
The Gross Law Firm Notifies Shareholders of Unicycive Therapeutics, Inc.(UNCY) of a Class Action Lawsuit and an Upcoming Deadline - Morningstar
ROSEN, A LEADING AND TOP RANKED LAW FIRM, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important October 14 Deadline in Securities Fraud Lawsuit – UNCY - GlobeNewswire Inc.
Join Class Action to Recover Losses from Unicycive Therapeutics, Inc. (UNCY)Contact Levi & Korsinsky Before October 14, 2025 - ACCESS Newswire
UNCY INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics - GlobeNewswire
Recover Investment Losses: Class Action Initiated Against Unicycive Therapeutics, Inc. (UNCY) - ACCESS Newswire
Holzer & Holzer, LLC Reminds Investors of Upcoming Lead - GlobeNewswire
UNICYCIVE REMINDER: Bragar Eagel & Squire, P.C. Urges - GlobeNewswire
UNCY Stockholders Have Opportunity to Lead Unicycive Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
UNCY LAWSUIT ALERT: Levi & Korsinsky Notifies Unicycive Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - Morningstar
ROSEN, REGARDED INVESTOR COUNSEL, Encourages Unicycive - GlobeNewswire
ROSEN, REGARDED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure ... - Caledonian Record
Unicycive Therapeutics' (UNCY) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat
Investors in Unicycive Therapeutics, Inc. Should Contact - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Unicycive Therapeutics, Inc. Investors - GlobeNewswire
Shareholders SueWallSt in New Class Action Against Unicycive Therapeutics, Inc.Act Now - Nasdaq
Class Action Filed Against Unicycive Therapeutics, Inc. (UNCY) Seeking Recovery for InvestorsContact The Gross Law Firm - Barchart.com
UNCY Investors have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire
Investors in Unicycive Therapeutics, Inc. (UNCY): Protect Your RightsContact Levi & Korsinsky Before October 14, 2025 - Newsfile
UNCY DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics - GlobeNewswire
Attention Long-Term Shareholders of Amylyx Pharmaceuticals, - GlobeNewswire
Holzer & Holzer, LLC Reminds Investors of Upcoming October - GlobeNewswire
Investor Alert: Deadline Approaching to Join Unicycive Therapeutics, Inc. (UNCY) Class ActionContact Levi & Korsinsky - Newsfile
Important Notice to Long-Term Shareholders of Humana Inc. - GlobeNewswire
Shareholders that lost money on Unicycive Therapeutics, Inc.(UNCY) Urged to Join Class ActionContact The Gross Law Firm to Learn More - Sahm
Lost Money on Unicycive Therapeutics, Inc. (UNCY)? Contact Levi & Korsinsky Before October 14, 2025 to Join Class Action - ACCESS Newswire
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure ... - Caledonian Record
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Unicycive - GlobeNewswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
UNCY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Unicycive Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
What machine learning models say about Unicycive Therapeutics Inc.July 2025 Market Mood & Precise Buy Zone Tips - newser.com
UNCY INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive - The National Law Review
Securities Fraud Class Action Filed Against Unicycive Therapeutics, Inc. (UNCY)Levi & Korsinsky Reminds Investors of October 14, 2025 - ACCESS Newswire
Did You Lose Money on Unicycive Therapeutics, Inc. (UNCY)? Levi & Korsinsky Urges Investors to Act Before October 14, 2025 - ACCESS Newswire
What analysts say about Unicycive Therapeutics Inc stockFundamental Stock Analysis & Small Investment Capital Tips - earlytimes.in
Unicycive Therapeutics: Interview With Founder & CEO Dr. Shalabh Gupta About The Kidney Therapy Company - Pulse 2.0
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Unicycive - GlobeNewswire
UNICYCIVE LAWSUIT ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive - MarketScreener
UNCY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Unicycive Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Press Telegram - FinancialContent
Is it too late to sell Unicycive Therapeutics Inc.July 2025 Analyst Calls & Community Trade Idea Sharing Platform - newser.com
Is Unicycive Therapeutics Inc. still worth holding after the dipJuly 2025 Patterns & Smart Swing Trading Techniques - newser.com
Advanced analytics toolkit walkthrough for Unicycive Therapeutics Inc.Quarterly Risk Review & Real-Time Chart Pattern Alerts - newser.com
UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, - GuruFocus
UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Morningstar
Unicycive Therapeutics, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsUNCY - MarketScreener
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Is Expected To Breakeven In The Near Future - simplywall.st
Unicycive Therapeutics Inc Stock (UNCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):